Trastuzumab-Induced Hepatotoxicity: A Case Report
Darko Vucicevic, Elizabeth J. Carey, Nina J. Karlin
Breast Care · 2013 · 4,416 citationsOpen access
Abstract
BACKGROUND: Trastuzumab is a humanized monoclonal antibody approved for the treatment of breast cancer with HER2 amplification and/or overexpression. There are only 2 prior cases of trastuzumab-related hepatotoxicity reported in the literature. CASE REPORT: We report the case of a 60-year-old woman who was treated with trastuzumab for stage I invasive ductal carcinoma of the right breast. She successfully completed 6 months of therapy when an increase in liver transaminases was noted on routine examination. A full work-up for causes of acute and chronic liver disease was negative. After review of the patient's medication list, trastuzumab was thought to be the most likely culprit for the liver injury, based on timing of administration and rise in liver enzymes.
Cite this paper
Vucicevic, D., Carey, E. J., & Karlin, N. J. (2013). Trastuzumab-induced hepatotoxicity: A case report. Breast Care, 8(2), 146–148. https://doi.org/10.1159/000346844
Read it with every claim anchored
Add this paper to a project, ask questions of it, and get answers that point to the exact passage.
Start freeRelated papers
- Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications.1979
- Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures.1981
- Comprehensive molecular portraits of human breast tumours2012
- Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins.1986
- Studies of the HER-2/ neu Proto-Oncogene in Human Breast and Ovarian Cancer1989
Metadata from OpenAlex (CC0). Citations are generated from the published record.